Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | F12 | P00748 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL25268266 | 0.94 | MAP4K4 (0.34) | MAP4K4PLGF12F11KLKB1 | |
| Formic Acid SCHEMBL30451900 | 0.94 | MAP4K4 (0.34) | MAP4K4PLGF12F11KLKB1 | |
| SCHEMBL26771007 | 0.91 | MAP4K4 (0.36) | MAP4K4ABL1MAPK14 | |
| SCHEMBL24252506 | 0.87 | MAP4K4 (0.37) | MAP4K4PLGF12F11KLKB1 | |
| SCHEMBL24252269 | 0.85 | DHFR (0.40) | MAP4K4PLGF12F11KLKB1 | |
| SCHEMBL24252663 | 0.85 | PLG (0.33) | PLGF12F11KLKB1PRSS1 | |
| SCHEMBL25214927 | 0.85 | MAP4K4 (0.33) | MAP4K4ABL1MAPK14 | |
| SCHEMBL24252277 | 0.84 | TRPA1 (0.34) | PLGF12F11KLKB1PRSS1 | |
| SCHEMBL24252366 | 0.84 | ABL1 (0.33) | PLGF12F11KLKB1PRSS1 | |
| SCHEMBL30451875 | 0.84 | ABL1 (0.33) | PLGF12F11KLKB1PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | MAP4K4 2769/4885PLG 260/4885F12 29/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | MAP4K4 2769/4885PLG 260/4885F12 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.